Adverum Biotechnologies, Inc.
ADVM
$3.08
$0.051.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | 1.00M | 1.00M | 1.00M | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | 1.00M | 1.00M | 1.00M | 0.00 |
| Cost of Revenue | 110.41M | 90.38M | 77.04M | 68.03M | 68.34M |
| Gross Profit | -109.41M | -89.38M | -76.04M | -67.03M | -68.34M |
| SG&A Expenses | 80.11M | 83.19M | 77.50M | 55.40M | 59.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 190.51M | 173.56M | 154.54M | 123.43M | 127.74M |
| Operating Income | -189.51M | -172.56M | -153.54M | -122.43M | -127.74M |
| Income Before Tax | -183.87M | -165.18M | -145.31M | -114.58M | -120.31M |
| Income Tax Expenses | -- | -- | -- | -1.13M | -1.12M |
| Earnings from Continuing Operations | -183.87 | -165.18 | -145.31 | -113.44 | -119.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -183.87M | -165.18M | -145.31M | -113.44M | -119.20M |
| EBIT | -189.51M | -172.56M | -153.54M | -122.43M | -127.74M |
| EBITDA | -186.60M | -169.22M | -149.89M | -118.58M | -123.27M |
| EPS Basic | -8.78 | -7.90 | -7.31 | -7.24 | -9.20 |
| Normalized Basic EPS | -5.49 | -4.94 | -4.57 | -4.60 | -5.82 |
| EPS Diluted | -8.78 | -7.90 | -7.31 | -7.24 | -9.20 |
| Normalized Diluted EPS | -5.49 | -4.94 | -4.57 | -4.60 | -5.82 |
| Average Basic Shares Outstanding | 83.72M | 83.56M | 79.11M | 68.33M | 57.55M |
| Average Diluted Shares Outstanding | 83.72M | 83.56M | 79.11M | 68.33M | 57.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |